| Real-world direct comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Medicare beneficiaries with atrial fibrillation L Yang, MM Brooks, NW Glynn, Y Zhang, S Saba, I Hernandez The American journal of cardiology 126, 29-36, 2020 | 15 | 2020 |
| Using machine learning to identify diabetes patients with canagliflozin prescriptions at high‐risk of lower extremity amputation using real‐world data L Yang, N Gabriel, I Hernandez, AG Winterstein, J Guo Pharmacoepidemiology and Drug Safety 30 (5), 644-651, 2021 | 11 | 2021 |
| Identifying patients at risk of acute kidney injury among medicare beneficiaries with type 2 diabetes initiating SGLT2 inhibitors: A machine learning approach L Yang, N Gabriel, I Hernandez, SM Vouri, SE Kimmel, J Bian, J Guo Frontiers in Pharmacology 13, 834743, 2022 | 6 | 2022 |
| Trajectories of sacubitril/valsartan adherence among Medicare beneficiaries with heart failure W Huang, MM Ahmed, EJ Morris, L Yang, L O'Neal, I Hernandez, J Bian, ... JACC: Advances, 100958, 2024 | 4 | 2024 |
| Primary care provider payment models and adherence to anticoagulation in patients with atrial fibrillation L Yang, J Guo, Q Liang, TV Newman, WF Gellad, I Hernandez Journal of managed care & specialty pharmacy 27 (12), 1672-1679, 2021 | 4 | 2021 |
| Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes WH Chen, Y Li, L Yang, JM Allen, H Shao, WT Donahoo, L Billelo, X Hu, ... Plos one 19 (1), e0297208, 2024 | 2 | 2024 |
| COVID-19 pandemic and initiation of treatment for atrial fibrillation: a nationwide analysis of claims data L Yang, S Tang, M He, J Guo, N Gabriel, G Swabe, WF Gellad, UR Essien, ... BMC Cardiovascular Disorders 23 (1), 604, 2023 | 2 | 2023 |
| COVID-19 pandemic and trends in clinical outcomes and medication use for patients with established atrial fibrillation: A nationwide analysis of claims data I Hernandez, L Yang, S Tang, T Cameron, J Guo, N Gabriel, UR Essien, ... American Heart Journal Plus: Cardiology Research and Practice 42, 100396, 2024 | 1 | 2024 |
| Individual and social determinants of adherence to sodium-glucose cotransporter 2 inhibitor therapy: A trajectory analysis L Yang, N Gabriel, J Bian, LA Bilello, DR Wright, I Hernandez, J Guo Journal of Managed Care & Specialty Pharmacy 29 (11), 1242-1251, 2023 | 1 | 2023 |
| PDG82 Machine Learning to Identify Diabetes Patients with Canagliflozin Prescriptions at High-Risk of Lower Extremity Amputation Using Real-Word DATA L Yang, N Gabriel, I Hernandez, S Guo Value in Health 23, S532, 2020 | 1 | 2020 |
| COVID-19 Diagnosis, Oral Anticoagulation, and Stroke Risk in Patients with Atrial Fibrillation L Yang, S Tang, J Guo, N Gabriel, WF Gellad, UR Essien, JW Magnani, ... American Journal of Cardiovascular Drugs, 1-10, 2024 | | 2024 |
| Effectiveness and Safety Outcomes of SGLT2 Inhibitors in Type 2 Diabetes and Use of Drugs with Nephrotoxic Potential L Yang University of Pittsburgh, 2024 | | 2024 |
| EPH147 Trajectories of Sacubitril/Valsartan Adherence Among Medicare Beneficiaries with Heart Failure W Huang, M Ahmed, S Smith, MM Hasan, M Rouhizadeh, J Bian, ... Value in Health 26 (6), S191, 2023 | | 2023 |
| Abstract P541: Trends in Initiation of Anticoagulation for Atrial Fibrillation in the Early Months of the COVID-19 Pandemic L Yang, S Tang, M He, J Guo, N Gabriel, G Swabe, W Gellad, UR Essien, ... Circulation 147 (Suppl_1), AP541-AP541, 2023 | | 2023 |
| POSC191 Group Based Trajectory Models to Identify Adherence Pattern to Sodium Glucose Cotransporter 2 Inhibitors Among Type 2 Diabetes Patients L Yang, N Gabriel, I Hernandez, J Guo Value in Health 25 (1), S138, 2022 | | 2022 |
| Association between primary care provider payment models and adherence to anticoagulation in a sample of patients with atrial fibrillation L Yang, J Guo, TV Newman, WF Gellad, I Hernandez PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 30, 149-150, 2021 | | 2021 |
| 782-P: Machine Learning to Identify Diabetes Patients Initiating SGLT2i at High-Risk of Acute Kidney Injury L Yang, N Gabriel, I Hernandez, AG Winterstein, S Kimmel, J Guo Diabetes 70 (Supplement_1), 2021 | | 2021 |
| PP181 Direct Comparison Of The Effectiveness And Safety Of Apixaban, Dabigatran, Rivaroxaban, And Warfarin: Subgroup Analyses Of Medicare Beneficiaries L Yang, MM Brooks, NW Glynn, Y Zhang, S Saba, I Hernandez International Journal of Technology Assessment in Health Care 36 (S1), 19-19, 2020 | | 2020 |
Inmaculada HernandezUniversity of California, San Diego在 health.ucsd.edu 的电子邮件经过验证
Inmaculada HernandezUniversity of California, San Diego在 health.ucsd.edu 的电子邮件经过验证
Jingchuan GuoUniversity of Florida在 ufl.edu 的电子邮件经过验证